Moleculin BiotechMBRX -1.86%30 3-Year ROIIC % is 871.97 as of Dec. 2025. GuruFocus rates MBRX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,320 Biotechnology companies, Moleculin Biotech ranks better than 93.71% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Moleculin Biotech's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 871.97%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Moleculin Biotech's 3-Year ROIIC % or its related term are showing as below:
MBRX's 3-Year ROIIC % is ranked better than 93.71% of 1320
companies
in the Biotechnology industry
Industry Median: -4.42
vs MBRX: 871.97
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Moleculin Biotech 3-Year ROIIC % Related Terms
Moleculin Biotech 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Moleculin Biotech's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MBRX vs JAGX, BCDA, AKTX: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Moleculin Biotech's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moleculin Biotech 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Moleculin Biotech's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Moleculin Biotech's 3-Year ROIIC % falls into.
Moleculin Biotech's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -25.103 (Dec. 2025) - -30.64 (Dec. 2022) )
/
( 12.577 (Dec. 2025) - 11.942 (Dec. 2022) )
=
5.537
/
0.635
=
871.97%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Moleculin Biotech (MBRX) has a 3-Year ROIIC % of 871.97 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Moleculin Biotech and its competitors. According to the industry distribution chart, Moleculin Biotech ranks #83 out of 1320 companies in the Biotechnology industry, placing it in the top 6.3%.
Is Moleculin Biotech's 3-Year ROIIC % too high?
Moleculin Biotech's current 3-Year ROIIC % is 871.97. Based on the distribution chart, Moleculin Biotech ranks #83 out of 1320 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Moleculin Biotech has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Moleculin Biotech's 3-Year ROIIC % compare to JAGX and BCDA?
According to the Biotechnology industry distribution chart, Moleculin Biotech ranks #83 out of 1320 companies for 3-Year ROIIC %. This places Moleculin Biotech in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Moleculin Biotech and its competitors. Moleculin Biotech's current 3-Year ROIIC % is 871.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moleculin Biotech stock overvalued right now?
Moleculin Biotech (MBRX) has a current 3-Year ROIIC % of 871.97. The current 3-Year ROIIC % is 871.97. Moleculin Biotech's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Moleculin Biotech (MBRX), the current 3-Year ROIIC % is 871.97 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
30GF Score
Get the complete analysis for MBRX
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBRX has been successfully added to your 
